Gastroenterology News

Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to a new study that also incorporated a predictive biomarker for response.

An abundance of Faecalibacterium prausnitzii or Roseburia hominis may predict the effectiveness of high-dose thiamine treatment to alleviate chronic fatigue in quiescent inflammatory bowel disease, according to research.

The treatment sequence of vedolizumab to adalimumab resulted in the lowest overall incidences of hospitalization and surgery in both Crohn’s disease and ulcerative colitis compared with other biologic treatment sequences, research showed.

Researchers have identified additional predictors of relapse in patients undergoing liver transplant for alcohol-related liver disease, including younger age and prior relapse, which differ from components of current prediction scores.

Physicians can use social media to combat medical misinformation that spreads through it, according to a speaker at the Osteopathic Medical Education Conference.

No significant differences were reported in clinical response at day 7 between 5 mg/kg and 10 kg/kg doses of infliximab in acute severe ulcerative colitis, nor were there differences in intensified, accelerated or standard dosing at month 3.

This year the Healio podcast, Gut Talk, celebrates its 5th anniversary of diving deep into the world of gastroenterology with a range of experts from across the field covering topics that matter most to patients and physicians.

When Tiffany McLellan was 18 years old, she was diagnosed with an ulcer in her digestive tract. She found relief with antacids for almost 2 years, but after her son was born, she started experiencing digestive issues and pain again.

Time in the market is far more important than timing the market. Long-term investors will utilize both the strategies of dollar cost averaging and lump sum investing to reach their investment goals.

Sodium-glucose cotransporter-2 inhibitors showed similar hepatic effectiveness to glucagon-like peptide-1 receptor agonists, especially among women and younger patients, in metabolic dysfunction-associated steatotic liver disease.